Overall pain · patients with adhesive capsulitis (frozen shoulder)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Function (change from baseline) Shoulder Pain and Disability Questionnaire (SPADI, 0‐100) (lower scores = better function)f · patients with adhesive capsulitis (frozen shoulder)
1 finding from 1 review
Global assessment of treatment success · patients with adhesive capsulitis (frozen shoulder)
Combination of manual therapy, exercise, electrotherapy and oral NSAID may leads to higher global assessment of treatment success "Disappearance of shoulder… compared with oral NSAID (low certainty).
1 finding from 1 review
Active shoulder abduction · patients with adhesive capsulitis (frozen shoulder)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · patients with adhesive capsulitis (frozen shoulder)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events Pain persisting longer than 2 hours after treatment (during the 3‐week treatment period) · patients with adhesive capsulitis (frozen shoulder)
Combination of manual therapy, exercise, electrotherapy and oral NSAID may leads to higher adverse events Pain persisting longer than 2 hours after treatment… compared with oral NSAID (low certainty).
1 finding from 1 review
Short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of · adults with alopecia areata
It is very uncertain whether summary of findings table ‐ Oral small molecule inhibitors… changes short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of compared with oral small molecule inhibitors (tofacitinib) (very low certainty).
1 finding from 1 review
Incidence of serious adverse events · adults with alopecia areata
1 finding from 1 review
Health‐related quality of life ‐ not reported · adults with alopecia areata
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Long‐term hair regrowth ≥ 75% (greater than 26 weeks of · adults with alopecia areata
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of · adults with alopecia areata
Summary of findings table ‐ Oral classical immunosuppressants… showed no clear difference in short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of compared with oral classical immunosuppressants (azathioprine, methotrexate,… (low certainty).
1 finding from 1 review
Incidence of serious adverse events · adults with alopecia areata
1 finding from 1 review
Health‐related quality of life ‐ not reported · adults with alopecia areata
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Long‐term hair regrowth ≥ 75% (greater than 26 weeks of · adults with alopecia areata
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Non‐fatal PE (3 to 12 months) · participants with diagnosed DVT
Oral factor Xa inhibitors showed no clear difference in non‐fatal PE (3 to 12 months) compared with conventional anticoagulation (moderate certainty).
1 finding from 1 review
All‐cause mortality (3 to 6 months) · participants with diagnosed DVT
Oral factor Xa inhibitors showed no clear difference in all‐cause mortality (3 to 6 months) compared with conventional anticoagulation (moderate certainty).
1 finding from 1 review
Major bleeding · participants with diagnosed DVT
Oral factor Xa inhibitors leads to lower major bleeding (3 to 12 months) compared with conventional anticoagulation (high certainty).
1 finding from 1 review
Recurrent VTE · participants with diagnosed DVT
Oral factor Xa inhibitors showed no clear difference in recurrent VTE (3 to 12 months) compared with conventional anticoagulation (moderate certainty).
1 finding from 1 review
Recurrent DVT (3 to 12 months) · participants with diagnosed DVT
Oral factor Xa inhibitors showed no clear difference in recurrent DVT (3 to 12 months) compared with conventional anticoagulation (moderate certainty).
1 finding from 1 review
Fatal PE (3 to 12 months) · participants with diagnosed DVT
Oral factor Xa inhibitors showed no clear difference in fatal PE (3 to 12 months) compared with conventional anticoagulation (moderate certainty).
1 finding from 1 review